Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Publications

Search Items: DIABETES MELLITUS, TYPE 2 - DRUG THERAPY , . hits: 74

2023

Obermayer, A; Tripolt, NJ; Pferschy, PN; Kojzar, H; Aziz, F; Müller, A; Schauer, M; Oulhaj, A; Aberer, F; Sourij, C; Habisch, H; Madl, T; Pieber, T; Obermayer-Pietsch, B; Stadlbauer, V; Sourij, H Efficacy and Safety of Intermittent Fasting in People With Insulin-Treated Type 2 Diabetes (INTERFAST-2)-A Randomized Controlled Trial.
Diabetes Care. 2023; 46(2):463-468 Doi: 10.2337/dc22-1622 [OPEN ACCESS]
PubMed FullText FullText_MUG

Osto, E; Bonacina, F; Pirillo, A; Norata, GD Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms.
Pharmacol Res. 2023; 188: 106667 Doi: 10.1016/j.phrs.2023.106667
Web of Science PubMed FullText FullText_MUG

2022

Obermayer, A; Tripolt, NJ; Pferschy, PN; Kojzar, H; Jacan, A; Schauer, M; Aziz, F; Oulhaj, A; Aberer, F; Sourij, C; Obermayer-Pietsch, B; Stadlbauer, V; Sourij, H INTERmittent FASTing in people with insulin-treated type 2 diabetes mellitus - the INTERFAST-2 study protocol.
Diabet Med. 2022; 39(6):e14813 Doi: 10.1111/dme.14813 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2021

Hochfellner, DA; Rainer, R; Ziko, H; Aberer, F; Simic, A; Lichtenegger, KM; Beck, P; Donsa, K; Pieber, TR; Fruhwald, FM; Rosenkranz, AR; Kamolz, LP; Baumann, PM; Mader, JK; Plank, J Efficient and safe glycaemic control with basal-bolus insulin therapy during fasting periods in hospitalized patients with type 2 diabetes using decision support technology: A post hoc analysis.
Diabetes Obes Metab. 2021; 23(9):2161-2169 Doi: 10.1111/dom.14458
Web of Science PubMed FullText FullText_MUG

Schnedl, WJ; Holasek, SJ; Schenk, M; Enko, D; Mangge, H Diagnosis of hepatic nuclear factor 1A monogenic diabetes mellitus (HNF1A-MODY) impacts antihyperglycemic treatment.
Wien Klin Wochenschr. 2021; 133(5-6):241-244 Doi: 10.1007/s00508-020-01770-2
Web of Science PubMed FullText FullText_MUG

Tarride, JE; Husain, M; Andersen, A; Gundgaard, J; Luckevich, M; Mark, T; Wagner, L; Pieber, TR Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial.
J Med Econ. 2021; 24(1): 1318-1326. Doi: 10.1080/13696998.2021.2003804
Web of Science PubMed FullText FullText_MUG

2020

Priyambada, L; Wolfsdorf, JI; Brink, SJ; Fritsch, M; Codner, E; Donaghue, KC; Craig, ME ISPAD Clinical Practice Consensus Guideline: Diabetic ketoacidosis in the time of COVID-19 and resource-limited settings-role of subcutaneous insulin.
Pediatr Diabetes. 2020; 21(8):1394-1402 Doi: 10.1111/pedi.13118 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2019

Clodi, M; Abrahamian, H; Brath, H; Brix, J; Drexel, H; Fasching, P; Föger, B; Francesconi, C; Fröhlich-Reiterer, E; Harreiter, J; Hofer, SE; Hoppichler, F; Huber, J; Kaser, S; Kautzky-Willer, A; Lechleitner, M; Ludvik, B; Luger, A; Mader, JK; Paulweber, B; Pieber, T; Prager, R; Rami-Merhar, B; Resl, M; Riedl, M; Roden, M; Saely, CH; Schelkshorn, C; Schernthaner, G; Sourij, H; Stechemesser, L; Stingl, H; Toplak, H; Wascher, TC; Weitgasser, R; Winhofer-Stöckl, Y; Zlamal-Fortunat, S [Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2019)].
Wien Klin Wochenschr. 2019; 131(Suppl 1):27-38 Doi: 10.1007/s00508-019-1471-z [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Lechleitner, M; Clodi, M; Abrahamian, H; Brath, H; Brix, J; Drexel, H; Fasching, P; Föger, B; Francesconi, C; Fröhlich-Reiterer, E; Harreiter, J; Hofer, SE; Hoppichler, F; Huber, J; Kaser, S; Kautzky-Willer, A; Ludvik, B; Luger, A; Mader, JK; Paulweber, B; Pieber, T; Prager, R; Rami-Merhar, B; Resl, M; Riedl, M; Roden, M; Saely, CH; Schelkshorn, C; Schernthaner, G; Sourij, H; Stechemesser, L; Stingl, H; Toplak, H; Wascher, TC; Weitgasser, R; Winhofer-Stöckl, Y; Zlamal-Fortunat, S [Insulin therapy of type 2 diabetes mellitus (Update 2019)].
Wien Klin Wochenschr. 2019; 131(Suppl 1):39-46 Doi: 10.1007/s00508-019-1492-7
Web of Science PubMed FullText FullText_MUG

Parhofer, KG; Birkenfeld, AL; Krone, W; Lehrke, M; Marx, N; Merkel, M; Schütt, KS; Zirlik, A; Müller-Wieland, D Position Paper on Lipid Therapy in Patients with Diabetes Mellitus.
Exp Clin Endocrinol Diabetes. 2019; 127(S 01):S97-S101 Doi: 10.1055/a-1018-9228 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Pratley, RE; Husain, M; Lingvay, I; Pieber, TR; Mark, T; Saevereid, HA; Møller, DV; Zinman, B; DEVOTE Study Group Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
Cardiovasc Diabetol. 2019; 18(1):156-156 Doi: 10.1186/s12933-019-0960-8 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Wiviott, SD; Raz, I; Bonaca, MP; Mosenzon, O; Kato, ET; Cahn, A; Silverman, MG; Zelniker, TA; Kuder, JF; Murphy, SA; Bhatt, DL; Leiter, LA; McGuire, DK; Wilding, JPH; Ruff, CT; Gause-Nilsson, IAM; Fredriksson, M; Johansson, PA; Langkilde, AM; Sabatine, MS; DECLARE–TIMI 58 Investigators Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med. 2019; 380(4): 347-357. Doi: 10.1056/NEJMoa1812389 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2018

Pieber, TR; Marso, SP; McGuire, DK; Zinman, B; Poulter, NR; Emerson, SS; Pratley, RE; Woo, V; Heller, S; Lange, M; Brown-Frandsen, K; Moses, A; Barner Lekdorf, J; Lehmann, L; Kvist, K; Buse, JB; DEVOTE Study Group DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality.
Diabetologia. 2018; 61(1):58-65 Doi: 10.1007/s00125-017-4422-0 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Tripolt, NJ; Aberer, F; Riedl, R; Url, J; Dimsity, G; Meinitzer, A; Stojakovic, T; Aziz, F; Hödl, R; Brachtl, G; Strunk, D; Brodmann, M; Hafner, F; Sourij, H Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.
Cardiovasc Diabetol. 2018; 17(1):71-71 Doi: 10.1186/s12933-018-0716-x [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Zinman, B; Marso, SP; Poulter, NR; Emerson, SS; Pieber, TR; Pratley, RE; Lange, M; Brown-Frandsen, K; Moses, A; Ocampo Francisco, AM; Barner Lekdorf, J; Kvist, K; Buse, JB; DEVOTE Study Group Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).
Diabetologia. 2018; 61(1):48-57 Doi: 10.1007/s00125-017-4423-z [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2017

Davies, M; Pieber, TR; Hartoft-Nielsen, ML; Hansen, OKH; Jabbour, S; Rosenstock, J Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
JAMA. 2017; 318(15):1460-1470 Doi: 10.1001/jama.2017.14752 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Holman, RR; Bethel, MA; Mentz, RJ; Thompson, VP; Lokhnygina, Y; Buse, JB; Chan, JC; Choi, J; Gustavson, SM; Iqbal, N; Maggioni, AP; Marso, SP; Öhman, P; Pagidipati, NJ; Poulter, N; Ramachandran, A; Zinman, B; Hernandez, AF; EXSCEL Study Group Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med. 2017; 377(13): 1228-1239. Doi: 10.1056/NEJMoa1612917 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Marso, SP; McGuire, DK; Zinman, B; Poulter, NR; Emerson, SS; Pieber, TR; Pratley, RE; Haahr, PM; Lange, M; Brown-Frandsen, K; Moses, A; Skibsted, S; Kvist, K; Buse, JB; DEVOTE Study Group Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
N Engl J Med. 2017; 377(8):723-732 Doi: 10.1056/NEJMoa1615692 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Spat, S; Donsa, K; Beck, P; Höll, B; Mader, JK; Schaupp, L; Augustin, T; Chiarugi, F; Lichtenegger, KM; Plank, J; Pieber, TR A Mobile Computerized Decision Support System to Prevent Hypoglycemia in Hospitalized Patients With Type 2 Diabetes Mellitus.
J Diabetes Sci Technol. 2017; 11(1):20-28 Doi: 10.1177/1932296816676501 [OPEN ACCESS]
PubMed FullText FullText_MUG

Stegemann, S; Riedl, R; Sourij, H Identification of different shapes, colors and sizes of standard oral dosage forms in diabetes type 2 patients-A pilot study.
Int J Pharm. 2017; 517(1-2):112-118 Doi: 10.1016/j.ijpharm.2016.11.066
Web of Science PubMed FullText FullText_MUG

von Lewinski, D; Kolesnik, E; Wallner, M; Resl, M; Sourij, H New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data.
Biomed Res Int. 2017; 2017(9):1253425-1253425 Doi: 10.1155/2017/1253425 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2016

Abrahamian, H; Kautzky-Willer, A; Rießland-Seifert, A; Fasching, P; Ebenbichler, C; Hofmann, P; Toplak, H [Mental disorders and diabetes mellitus].
Wien Klin Wochenschr. 2016; 128 Suppl 2(4):S170-S178 Doi: 10.1007/s00508-015-0939-8 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Blevins, T; Pieber, TR; Colón Vega, G; Zhang, S; Bastyr, EJ; Chang, AM; IMAGINE 4 Investigators Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4.
Diabetes Obes Metab. 2016; 18(11):1072-1080 Doi: 10.1111/dom.12696 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Clodi, M; Abrahamian, H; Drexel, H; Fasching, P; Föger, B; Francesconi, C; Hoppichler, F; Kaser, S; Kautzky-Willer, A; Lechleitner, M; Ludvik, B; Prager, R; Fröhlich-Reiterer, E; Roden, M; Säly, C; Schernthaner, G; Sourij, H; Toplak, H; Wascher, TC; Weitgasser, R [Antihyperglycemic treatment guidelines for diabetes mellitus type 2].
Wien Klin Wochenschr. 2016; 128 Suppl 2(4):S45-S53 Doi: 10.1007/s00508-016-0991-z [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Donsa, K; Beck, P; Höll, B; Mader, JK; Schaupp, L; Plank, J; Neubauer, KM; Baumgartner, C; Pieber, TR Impact of errors in paper-based and computerized diabetes management with decision support for hospitalized patients with type 2 diabetes. A post-hoc analysis of a before and after study.
Int J Med Inform. 2016; 90(2):58-67 Doi: 10.1016/j.ijmedinf.2016.03.007
Web of Science PubMed FullText FullText_MUG

Ferrannini, E; Baldi, S; Frascerra, S; Astiarraga, B; Heise, T; Bizzotto, R; Mari, A; Pieber, TR; Muscelli, E Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Diabetes. 2016; 65(5):1190-1195 Doi: 10.2337/db15-1356 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Heise, T; Korsatko, S; Nosek, L; Coester, HV; Deller, S; Roepstorff, C; Segel, S; Kapur, R; Haahr, H; Hompesch, M Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action.
J Diabetes. 2016; 8(1):132-138 Doi: 10.1111/1753-0407.12266
Web of Science PubMed FullText FullText_MUG

Holman, RR; Bethel, MA; George, J; Sourij, H; Doran, Z; Keenan, J; Khurmi, NS; Mentz, RJ; Oulhaj, A; Buse, JB; Chan, JC; Iqbal, N; Kundu, S; Maggioni, AP; Marso, SP; Öhman, P; Pencina, MJ; Poulter, N; Porter, LE; Ramachandran, A; Zinman, B; Hernandez, AF Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.
Am Heart J. 2016; 174(6):103-110 Doi: 10.1016/j.ahj.2015.12.009 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Marso, SP; McGuire, DK; Zinman, B; Poulter, NR; Emerson, SS; Pieber, TR; Pratley, RE; Haahr, PM; Lange, M; Frandsen, KB; Rabøl, R; Buse, JB Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1.
Am Heart J. 2016; 179(19-20):175-183 Doi: 10.1016/j.ahj.2016.06.004 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Rami-Merhar, B; Fröhlich-Reiterer, E; Hofer, SE Diabetes in the youth].
Wien Klin Wochenschr. 2016; 128 Suppl 2(3):S119-S123 Doi: 10.1007/s00508-015-0922-4 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Riedl, R; Robausch, M; Berghold, A The Evaluation of the Effectiveness of Austrians Disease Management Program in Patients with Type 2 Diabetes Mellitus - A Population-Based Retrospective Cohort Study.
PLoS One. 2016; 11(8):e0161429-e0161429 Doi: 10.1371/journal.pone.0161429 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Rodbard, HW; Cariou, B; Pieber, TR; Endahl, LA; Zacho, J; Cooper, JG Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.
Diabetes Obes Metab. 2016; 18(3):274-280 Doi: 10.1111/dom.12609 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Tripolt, NJ; Aberer, F; Riedl, R; Hutz, B; Url, J; Dimsity, G; Meinitzer, A; Stojakovic, T; Hödl, R; Brodmann, M; Hafner, F; Sourij, H The effects of linagliptin on endothelial function and global arginine bioavailability ratio in coronary artery disease patients with early diabetes: study protocol for a randomized controlled trial.
Trials. 2016; 17(1):495-495 Doi: 10.1186/s13063-016-1627-3 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2015

Hermanns, N; Lilly, LC; Mader, JK; Aberer, F; Ribitsch, A; Kojzar, H; Warner, J; Pieber, TR Novel simple insulin delivery device reduces barriers to insulin therapy in type 2 diabetes: results from a pilot study.
J Diabetes Sci Technol. 2015; 9(3):581-587 Doi: 10.1177/1932296815570709 [OPEN ACCESS]
PubMed FullText FullText_MUG

Muschitz, C; Thaler, HW; Dimai, HP; Resch, H; Kocijan, R; Kostic, M; Geiger, C; Kaider, A; Muschitz, GK; Szivak, M; Pietschmann, P Atypical Femoral Fractures-Ongoing and History of Bone-Specific Therapy, Concomitant Diseases, Medications, and Survival.
J Clin Densitom. 2015; 19(3):359-367 Doi: 10.1016/j.jocd.2015.05.070
Web of Science PubMed FullText FullText_MUG

Neubauer, KM; Mader, JK; Höll, B; Aberer, F; Donsa, K; Augustin, T; Schaupp, L; Spat, S; Beck, P; Fruhwald, FM; Schnedl, C; Rosenkranz, AR; Lumenta, DB; Kamolz, LP; Plank, J; Pieber, TR Standardized Glycemic Management with a Computerized Workflow and Decision Support System for Hospitalized Patients with Type 2 Diabetes on Different Wards.
Diabetes Technol Ther. 2015; 17(10):685-692 Doi: 10.1089/dia.2015.0027 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Schaupp, L; Donsa, K; Neubauer, KM; Mader, JK; Aberer, F; Höll, B; Spat, S; Augustin, T; Beck, P; Pieber, TR; Plank, J Taking a Closer Look--Continuous Glucose Monitoring in Non-Critically Ill Hospitalized Patients with Type 2 Diabetes Mellitus Under Basal-Bolus Insulin Therapy.
Diabetes Technol Ther. 2015; 17(9):611-618 Doi: 10.1089/dia.2014.0343
Web of Science PubMed FullText FullText_MUG

2014

Holman, RR; Sourij, H; Califf, RM Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes.
Lancet. 2014; 383(9933):2008-2017 Doi: 10.1016/S0140-6736(14)60794-7
Web of Science PubMed FullText FullText_MUG

Mader, JK; Lilly, LC; Aberer, F; Korsatko, S; Strock, E; Mazze, RS; Damsbo, P; Pieber, TR A feasibility study of a 3-day basal-bolus insulin delivery device in individuals with type 2 diabetes.
Diabetes Care. 2014; 37(5):1476-1479 Doi: 10.2337/dc13-2238 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Mader, JK; Neubauer, KM; Schaupp, L; Augustin, T; Beck, P; Spat, S; Höll, B; Treiber, GM; Fruhwald, FM; Pieber, TR; Plank, J Efficacy, usability and sequence of operations of a workflow-integrated algorithm for basal-bolus insulin therapy in hospitalized type 2 diabetes patients.
Diabetes Obes Metab. 2014; 16(2):137-146 Doi: 10.1111/dom.12186 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Oh, DY; Walenta, E; Akiyama, TE; Lagakos, WS; Lackey, D; Pessentheiner, AR; Sasik, R; Hah, N; Chi, TJ; Cox, JM; Powels, MA; Di Salvo, J; Sinz, C; Watkins, SM; Armando, AM; Chung, H; Evans, RM; Quehenberger, O; McNelis, J; Bogner-Strauss, JG; Olefsky, JM A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice.
Nat Med. 2014; 20(8): 942-947. Doi: 10.1038/nm.3614 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Schmidt, LJ; Habacher, W; Augustin, T; Krahulec, E; Semlitsch, T A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes.
Diabetes Obes Metab. 2014; 16(9):769-779 Doi: 10.1111/dom.12269
Web of Science PubMed FullText FullText_MUG

Tripolt, NJ; Narath, SH; Eder, M; Pieber, TR; Wascher, TC; Sourij, H Multiple risk factor intervention reduces carotid atherosclerosis in patients with type 2 diabetes.
Cardiovasc Diabetol. 2014; 13(7):95-95 Doi: 10.1186/1475-2840-13-95 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2013

Konrad, K; Scheuing, N; Badenhoop, K; Borkenstein, MH; Gohlke, B; Schöfl, C; Seufert, J; Thon, A; Holl, RW Cystic fibrosis-related diabetes compared with type 1 and type 2 diabetes in adults.
Diabetes Metab Res Rev. 2013; 29(7):568-575 Doi: 10.1002/dmrr.2429
Web of Science PubMed FullText FullText_MUG

Pilz, S; Kienreich, K; Rutters, F; de Jongh, R; van Ballegooijen, AJ; Grübler, M; Tomaschitz, A; Dekker, JM Role of vitamin D in the development of insulin resistance and type 2 diabetes.
Curr Diab Rep. 2013; 13(2):261-270 Doi: 10.1007/s11892-012-0358-4
Web of Science PubMed FullText FullText_MUG

2012

Clodi, M; Abrahamian, HE; Drexel, H; Fasching, P; Hoppichler, F; Kautzky-Willer, A; Lechleitner, M; Ludvik, B; Prager, R; Roden, M; Saely, C; Schernthaner, G; Schober, E; Toplak, H; Wascher, T; Weitgasser, R Antihyperglycemic Treatment Guidelines for diabetes mellitus type 2].
Wien Klin Wochenschr. 2012; 124 Suppl 2(4):10-16 Doi: 10.1007/s00508-012-0263-5 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

König, A; Bode, C; Bugger, H Diabetes mellitus and myocardial mitochondrial dysfunction: bench to bedside.
Heart Fail Clin. 2012; 8(4): 551-561. Doi: 10.1016/j.hfc.2012.06.001
Web of Science PubMed FullText FullText_MUG

2011

Hancu, N; Czupryniak, L; Genestin, E; Sourij, H A Pan-European and Canadian prospective survey to evaluate patient satisfaction with the SoloSTAR insulin injection device in type 1 and type 2 diabetes.
J Diabetes Sci Technol. 2011; 5(5):1224-1234 Doi: 10.1177/193229681100500531 [OPEN ACCESS]
PubMed FullText FullText_MUG

Sourij, H; Schmoelzer, I; de Campo, A; Tripolt, NJ; Stojakovic, T; Scharnagl, H; Kettler-Schmut, E; Forst, T; Wascher, TC Non-glycemic effects of insulin therapy: a comparison between insulin aspart and regular human insulin during two consecutive meals in patients with type 2 diabetes.
Eur J Endocrinol. 2011; 165(2): 269-274. Doi: 10.1530/EJE-11-0061 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2009

Dalla Man, C; Bock, G; Giesler, PD; Serra, DB; Ligueros Saylan, M; Foley, JE; Camilleri, M; Toffolo, G; Cobelli, C; Rizza, RA; Vella, A Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes.
Diabetes Care. 2009; 32(1):14-18 Doi: 10.2337/dc08-1512 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Show the next 50 results of search

↑ Top of page / Navigation